| Lighthouse Associates Llc | |
|
5705 W Johnson Rd Ludington MI 49431-1516 | |
| (231) 425-4414 | |
| (231) 425-4434 |
| Full Name | Lighthouse Associates Llc |
|---|---|
| Speciality | Social Worker |
| Location | 5705 W Johnson Rd, Ludington, Michigan |
| Authorized Official Name and Position | Lisa A Bradley (PRESIDENT) |
| Authorized Official Contact | 2314254414 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Lighthouse Associates Llc 5705 W Johnson Rd Ludington MI 49431-1516 Ph: (231) 425-4414 | Lighthouse Associates Llc 5705 W Johnson Rd Ludington MI 49431-1516 Ph: (231) 425-4414 |
| NPI Number | 1053759589 |
|---|---|
| Provider Enumeration Date | 06/06/2013 |
| Last Update Date | 03/14/2024 |
| Certification Date | 03/14/2024 |
| Medicare PECOS PAC ID | 0547403867 |
|---|---|
| Medicare Enrollment ID | O20130905000101 |
News Archive
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.
Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies.
Today the new Christian Doppler Laboratory for Complement Research was opened at the Center for Pathophysiology, Infectiology and Immunology at MedUni Vienna. The research institute, which is funded by the Federal Ministry of Science, Research and Economic Affairs (BMWFW) is concentrating on a special protein that is thought to play an important role in controlling excessive immune reactions.
Missouri lawmakers voted Wednesday to override Gov. Jay Nixon's veto and allow employers to refuse to provide health insurance coverage for birth control if doing so violates their religious convictions. But almost immediately after the vote, a Kansas City firefighter and the Greater Kansas City Coalition of Labor Union Women filed a lawsuit asking a judge to throw the new law out.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053759589 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | LB064630 (Michigan) | Primary |
| Provider Name | Lisa A Bradley |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1154310720 PECOS PAC ID: 4385612837 Enrollment ID: I20040922000452 |
News Archive
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.
Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies.
Today the new Christian Doppler Laboratory for Complement Research was opened at the Center for Pathophysiology, Infectiology and Immunology at MedUni Vienna. The research institute, which is funded by the Federal Ministry of Science, Research and Economic Affairs (BMWFW) is concentrating on a special protein that is thought to play an important role in controlling excessive immune reactions.
Missouri lawmakers voted Wednesday to override Gov. Jay Nixon's veto and allow employers to refuse to provide health insurance coverage for birth control if doing so violates their religious convictions. But almost immediately after the vote, a Kansas City firefighter and the Greater Kansas City Coalition of Labor Union Women filed a lawsuit asking a judge to throw the new law out.
› Verified 5 days ago
| Provider Name | Kathryn A Cain |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1730178534 PECOS PAC ID: 9739157298 Enrollment ID: I20040922000468 |
News Archive
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.
Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies.
Today the new Christian Doppler Laboratory for Complement Research was opened at the Center for Pathophysiology, Infectiology and Immunology at MedUni Vienna. The research institute, which is funded by the Federal Ministry of Science, Research and Economic Affairs (BMWFW) is concentrating on a special protein that is thought to play an important role in controlling excessive immune reactions.
Missouri lawmakers voted Wednesday to override Gov. Jay Nixon's veto and allow employers to refuse to provide health insurance coverage for birth control if doing so violates their religious convictions. But almost immediately after the vote, a Kansas City firefighter and the Greater Kansas City Coalition of Labor Union Women filed a lawsuit asking a judge to throw the new law out.
› Verified 5 days ago
| Provider Name | Paula Kathleen Wietrzykowski |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1912959479 PECOS PAC ID: 9537127535 Enrollment ID: I20041222000171 |
News Archive
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.
Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies.
Today the new Christian Doppler Laboratory for Complement Research was opened at the Center for Pathophysiology, Infectiology and Immunology at MedUni Vienna. The research institute, which is funded by the Federal Ministry of Science, Research and Economic Affairs (BMWFW) is concentrating on a special protein that is thought to play an important role in controlling excessive immune reactions.
Missouri lawmakers voted Wednesday to override Gov. Jay Nixon's veto and allow employers to refuse to provide health insurance coverage for birth control if doing so violates their religious convictions. But almost immediately after the vote, a Kansas City firefighter and the Greater Kansas City Coalition of Labor Union Women filed a lawsuit asking a judge to throw the new law out.
› Verified 5 days ago
| Provider Name | Patricia A Murphy Ruhlig |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1063834679 PECOS PAC ID: 3375774300 Enrollment ID: I20140314001820 |
News Archive
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.
Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies.
Today the new Christian Doppler Laboratory for Complement Research was opened at the Center for Pathophysiology, Infectiology and Immunology at MedUni Vienna. The research institute, which is funded by the Federal Ministry of Science, Research and Economic Affairs (BMWFW) is concentrating on a special protein that is thought to play an important role in controlling excessive immune reactions.
Missouri lawmakers voted Wednesday to override Gov. Jay Nixon's veto and allow employers to refuse to provide health insurance coverage for birth control if doing so violates their religious convictions. But almost immediately after the vote, a Kansas City firefighter and the Greater Kansas City Coalition of Labor Union Women filed a lawsuit asking a judge to throw the new law out.
› Verified 5 days ago
| Provider Name | Trudie M Brandt |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1578985966 PECOS PAC ID: 6800027996 Enrollment ID: I20140403000861 |
News Archive
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.
Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies.
Today the new Christian Doppler Laboratory for Complement Research was opened at the Center for Pathophysiology, Infectiology and Immunology at MedUni Vienna. The research institute, which is funded by the Federal Ministry of Science, Research and Economic Affairs (BMWFW) is concentrating on a special protein that is thought to play an important role in controlling excessive immune reactions.
Missouri lawmakers voted Wednesday to override Gov. Jay Nixon's veto and allow employers to refuse to provide health insurance coverage for birth control if doing so violates their religious convictions. But almost immediately after the vote, a Kansas City firefighter and the Greater Kansas City Coalition of Labor Union Women filed a lawsuit asking a judge to throw the new law out.
› Verified 5 days ago
| Provider Name | Devin A Gill |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1609143569 PECOS PAC ID: 6709191281 Enrollment ID: I20150812007980 |
News Archive
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.
Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies.
Today the new Christian Doppler Laboratory for Complement Research was opened at the Center for Pathophysiology, Infectiology and Immunology at MedUni Vienna. The research institute, which is funded by the Federal Ministry of Science, Research and Economic Affairs (BMWFW) is concentrating on a special protein that is thought to play an important role in controlling excessive immune reactions.
Missouri lawmakers voted Wednesday to override Gov. Jay Nixon's veto and allow employers to refuse to provide health insurance coverage for birth control if doing so violates their religious convictions. But almost immediately after the vote, a Kansas City firefighter and the Greater Kansas City Coalition of Labor Union Women filed a lawsuit asking a judge to throw the new law out.
› Verified 5 days ago
| Provider Name | Alicia M Kaja |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1114458668 PECOS PAC ID: 3072922426 Enrollment ID: I20210514001260 |
News Archive
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.
Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies.
Today the new Christian Doppler Laboratory for Complement Research was opened at the Center for Pathophysiology, Infectiology and Immunology at MedUni Vienna. The research institute, which is funded by the Federal Ministry of Science, Research and Economic Affairs (BMWFW) is concentrating on a special protein that is thought to play an important role in controlling excessive immune reactions.
Missouri lawmakers voted Wednesday to override Gov. Jay Nixon's veto and allow employers to refuse to provide health insurance coverage for birth control if doing so violates their religious convictions. But almost immediately after the vote, a Kansas City firefighter and the Greater Kansas City Coalition of Labor Union Women filed a lawsuit asking a judge to throw the new law out.
› Verified 5 days ago
| Provider Name | Amy L Billings |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1811440043 PECOS PAC ID: 0042617672 Enrollment ID: I20210924001717 |
News Archive
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.
Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies.
Today the new Christian Doppler Laboratory for Complement Research was opened at the Center for Pathophysiology, Infectiology and Immunology at MedUni Vienna. The research institute, which is funded by the Federal Ministry of Science, Research and Economic Affairs (BMWFW) is concentrating on a special protein that is thought to play an important role in controlling excessive immune reactions.
Missouri lawmakers voted Wednesday to override Gov. Jay Nixon's veto and allow employers to refuse to provide health insurance coverage for birth control if doing so violates their religious convictions. But almost immediately after the vote, a Kansas City firefighter and the Greater Kansas City Coalition of Labor Union Women filed a lawsuit asking a judge to throw the new law out.
› Verified 5 days ago
| Provider Name | Heidi L Goehmann |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1346692084 PECOS PAC ID: 1456749142 Enrollment ID: I20211029000926 |
News Archive
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.
Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies.
Today the new Christian Doppler Laboratory for Complement Research was opened at the Center for Pathophysiology, Infectiology and Immunology at MedUni Vienna. The research institute, which is funded by the Federal Ministry of Science, Research and Economic Affairs (BMWFW) is concentrating on a special protein that is thought to play an important role in controlling excessive immune reactions.
Missouri lawmakers voted Wednesday to override Gov. Jay Nixon's veto and allow employers to refuse to provide health insurance coverage for birth control if doing so violates their religious convictions. But almost immediately after the vote, a Kansas City firefighter and the Greater Kansas City Coalition of Labor Union Women filed a lawsuit asking a judge to throw the new law out.
› Verified 5 days ago
News Archive
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.
Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies.
Today the new Christian Doppler Laboratory for Complement Research was opened at the Center for Pathophysiology, Infectiology and Immunology at MedUni Vienna. The research institute, which is funded by the Federal Ministry of Science, Research and Economic Affairs (BMWFW) is concentrating on a special protein that is thought to play an important role in controlling excessive immune reactions.
Missouri lawmakers voted Wednesday to override Gov. Jay Nixon's veto and allow employers to refuse to provide health insurance coverage for birth control if doing so violates their religious convictions. But almost immediately after the vote, a Kansas City firefighter and the Greater Kansas City Coalition of Labor Union Women filed a lawsuit asking a judge to throw the new law out.
› Verified 5 days ago
Serenity Point Counseling And Wellness Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 901 S Washington Ave, Ludington, MI 49431 Phone: 231-425-3180 Fax: 231-425-4951 | |
Rhythm Of Life Counseling Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 121 Nelson Rd, Ludington, MI 49431 Phone: 231-690-9637 Fax: 989-894-5874 | |
Lakeshore Regional Entity Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 920 Diana St, Ludington, MI 49431 Phone: 231-845-6294 Fax: 231-845-7095 | |
Matthew D Smekar Lpc Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 307 S James St Ste 105, Ludington, MI 49431 Phone: 231-233-9120 | |
Spectrum Health Medical Group Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 7 N Atkinson Dr, Ludington, MI 49431 Phone: 231-845-5085 | |
Lifespan Behavioral Health Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1686 N Lakeshore Dr, Ludington, MI 49431 Phone: 231-233-6576 Fax: 231-845-7095 |